Estimated prevalence of pooled FVIII-binding Igs
| Cohort . | Sample size (n) . | Prevalence of pooled FVIII-binding Igs with titers ≥1:20 % (95% CI) . | Prevalence of pooled FVIII-binding Igs with confirmed FVIII specificity* % (95% CI) . |
|---|---|---|---|
| nsHA | 81 | 67.9 (57.1-77.1) | 40.7 (30.7-51.6) |
| sHA | 39 | 53.8 (38.6-68.4) | 25.6 (14.6-41.1) |
| healthy | 90 | 37.8 (28.5-48.1) | 12.2 (7.0-20.6) |
| Cohort . | Sample size (n) . | Prevalence of pooled FVIII-binding Igs with titers ≥1:20 % (95% CI) . | Prevalence of pooled FVIII-binding Igs with confirmed FVIII specificity* % (95% CI) . |
|---|---|---|---|
| nsHA | 81 | 67.9 (57.1-77.1) | 40.7 (30.7-51.6) |
| sHA | 39 | 53.8 (38.6-68.4) | 25.6 (14.6-41.1) |
| healthy | 90 | 37.8 (28.5-48.1) | 12.2 (7.0-20.6) |
CI, confidence interval (acc. Wilson EB40 ); FVIII, factor VIII; Ig, immunoglobulin; nsHA, nonsevere hemophilia A patients; sHA, severe hemophilia A patients; healthy, healthy donors.
Only patients with FVIII-specific IgG1, IgG3, and IgA titers ≥1:40 and with FVIII-specific IgG2, IgG4, and IgM titers ≥1:80 were considered.